Efficacy and safety of nilotinib 300  mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study

Source: Leukemia Research - Category: Hematology Authors: Tags: Research paper Source Type: research